CPT 81426 Reimbursement Benchmarks & Policy | OpenPayer

Summary & Overview

CPT 81426: Whole Genome Reference Sequencing for Unexplained Disorders

CPT code 81426 is a specialized genetic testing procedure involving whole genome sequencing of a patient's relative to establish a reference genome for comparison. This approach is crucial in evaluating unexplained disorders or syndromes, offering clinicians a powerful tool for identifying genetic causes when conventional diagnostics fall short. The code is recognized by major national payers, including Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare, reflecting its clinical importance and broad coverage.

This publication provides an in-depth overview of 81426, including payer coverage, clinical context, and relevant benchmarks. Readers will gain insight into the procedure's role in medical genetics, typical sites of service, and its relationship to other genetic testing codes. Policy updates and billing considerations are also discussed, helping stakeholders understand the evolving landscape of genetic testing reimbursement. The analysis highlights the significance of whole genome reference sequencing in advancing personalized medicine and improving diagnostic accuracy for complex cases.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcare81426genetic testingwhole genome sequencingmedical geneticsoffice settingclinical diagnosticsunexplained disordersreference genomeCPT codespolicy updates

CPT Code Overview

CPT code 81426 represents a comprehensive gene sequence analysis of the entire genome in a relative of the patient. This procedure is performed to create a reference genome gene sequence, which is then compared to the patient's genome to evaluate unexplained disorders or syndromes. The service type is genetic testing, and it is typically conducted in an office setting (Place of Service 11). This advanced analysis supports clinical decision-making in cases where a patient's condition cannot be explained by standard diagnostic methods.

Clinical & Coding Specifications

Clinical Context

A patient presents with an unexplained disorder or syndrome that has not been diagnosed through standard clinical evaluation. The clinician suspects a genetic etiology and orders a comprehensive genome sequencing analysis. To aid in interpretation, a relative of the patient (such as a parent or sibling) undergoes whole genome sequencing to create a reference genome. The laboratory compares the patient's genome to the relative's reference genome to identify potential pathogenic variants. This workflow is typically performed in an office setting (Place of Service 11) and is managed by specialists in medical genetics.

Coding Specifications

Modifiers:
- Modifier 26: Used to indicate the professional component of the service, such as interpretation and reporting by the physician or geneticist.
- Modifier 59: Used to denote a distinct procedural service, indicating that the procedure is separate from other services performed on the same day.
Provider Taxonomies:

Taxonomy Code	Specialty Name

National Reimbursement Benchmarks

Nationally, the mean rate for CPT code 81426 among commercial payers (BUCA average) is $1,907.71, which is substantially higher than the Aetna mean rate of $586.71. Blue Cross Blue Shield, Cigna, and UnitedHealth Group all report mean rates above $2,000, with UnitedHealth Group at $2,145.23, the highest among the listed payers.

Rate dispersion varies significantly across payers. Cigna exhibits the widest spread, with a difference of $2,344.50 between its 75th and 25th percentiles, indicating substantial variability in reimbursement. In contrast, Blue Cross Blue Shield shows a tighter range of $1,221.50, and UnitedHealth Group's range is $1,328.00. Aetna's percentiles are all zero, suggesting limited or no payment for most providers.

The table and chart below present the full breakdown of national mean rates and percentile distributions for each payer.

State Benchmarks

State: Alaska1 / 50

Alaska Benchmarks

Alaska exhibits a wide rate spread for CPT code 81426 across commercial payers. The largest spread is seen with UnitedHealth Group, where the 25th percentile ($5,019.00) and 75th percentile ($5,420.00) are both substantially higher than other payers, indicating a consistently high reimbursement. Blue Cross Blue Shield and BUCA also show notable spreads, with BUCA's 75th percentile ($4,559.10) nearly $1,600 above its 25th percentile ($2,957.60). Aetna's rates are lower overall, with both the 25th and 50th percentiles at $0.00, suggesting limited reimbursement at those levels.

Compared to national averages, Alaska's mean rates for all payers are markedly higher. For example, UnitedHealth Group's mean rate in Alaska is more than double its national mean, and Blue Cross Blue Shield's mean rate is nearly $1,600 above the national average. The table and chart below present the full breakdown of payer-specific rates in Alaska for CPT code 81426.

Key Insights for Alaska

UnitedHealth Group is the highest paying payer for CPT 81426 in Alaska, with a mean rate of $4,898.31.
Aetna is the lowest paying payer, with a mean rate of $1,996.42.
All Alaska payer mean rates are significantly higher than their respective national averages, with UnitedHealth Group and Blue Cross Blue Shield showing the largest deviations.

CPT 81416: CYP2C19 Gene Analysis, Common Variants

81432-GENOMIC-SEQUENCE-ANALYSIS-PANEL-TO-EVALUATE-THE-PATIENT

CPT 81432: Genomic Sequencing Panel for Hereditary Breast Cancer

81441-GENOMIC-SEQUENCE-ANALYSIS-PANEL-SOLID-ORGAN-NEOPLASM-DNA

CPT 81441: Genomic Sequence Analysis Panel for Solid Organ Neoplasms

81415-EXOME-EG-UNEXPLAINED-CONSTITUTIONAL-OR-HERITABLE-DISORDER

CPT 81415: Exome Sequence Analysis for Unexplained Heritable Disorders

81443-GENETIC-TESTING-FOR-SEVERE-INHERITED-CONDITIONS-EG-CYSTIC

CPT 81443: Genetic Testing Panel for Severe Inherited Conditions

81470-TEST-FOR-DETECTING-GENES-ASSOCIATED-WITH-INTELLECTUAL

CPT 81470: Genomic Sequencing for Intellectual Disability Detection

81425-GENOME-EG-UNEXPLAINED-CONSTITUTIONAL-OR-HERITABLE-DISORDER

CPT 81425: Genome Sequencing for Unexplained Heritable Disorders

81460-CPT-CODE-81460-AS-MAINTAINED-BY-AMERICAN-MEDICAL

CPT 81460: Genomic Sequencing Procedures for Genetic Testing

81434-HEREDITARY-BREAST-CANCERRELATED-DISORDERS-EG-HEREDITARY

CPT 81434: Hereditary Breast Cancer Genomic Sequence Analysis Panel

81422-GENOMIC-SEQUENCE-ANALYSIS-PANEL-TO-EVALUATE-CIRCULATING

CPT 81422: Genomic Sequence Analysis for Fetal Chromosomal Microdeletions

Showing 1–10 of 43

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

207SG0201X

OpenPayer

Summary & Overview

CPT 81426: Whole Genome Reference Sequencing for Unexplained Disorders

CPT Code Overview

Clinical & Coding Specifications

Clinical Context

Coding Specifications

National Reimbursement Benchmarks

State Benchmarks

Alaska Benchmarks

Key Insights for Alaska

Related Codes

Related Diagnoses

Related CPT Codes

National Reimbursement Benchmarks

State Benchmarks

Alaska Benchmarks

Key Insights for Alaska

Related Codes